Agilent Technologies (NYSE:A) Releases FY 2021 Earnings Guidance

Agilent Technologies (NYSE:A) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $4.280-$4.310 for the period, compared to the Thomson Reuters consensus estimate of $4.140. The company issued revenue guidance of $6.29 billion-$6.32 billion, compared to the consensus revenue estimate of $6.22 billion.Agilent Technologies also updated its Q4 2021 guidance to $1.150-$1.180 EPS.

Several equities research analysts have weighed in on the company. Societe Generale raised Agilent Technologies from a hold rating to a buy rating in a research report on Tuesday, June 22nd. KeyCorp increased their target price on Agilent Technologies from $160.00 to $195.00 and gave the stock an overweight rating in a research report on Wednesday, August 18th. Stifel Nicolaus raised their price target on Agilent Technologies from $136.00 to $162.00 and gave the company a hold rating in a report on Wednesday, August 18th. raised their price target on Agilent Technologies from $150.00 to $160.00 and gave the company a buy rating in a report on Wednesday, May 26th. Finally, Cowen raised their price target on Agilent Technologies from $165.00 to $200.00 and gave the company an outperform rating in a report on Friday. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. Based on data from, Agilent Technologies currently has an average rating of Buy and a consensus target price of $140.62.

Shares of NYSE:A traded up $0.41 during midday trading on Friday, reaching $173.69. The company had a trading volume of 11,274 shares, compared to its average volume of 1,666,982. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.63 and a current ratio of 2.11. Agilent Technologies has a 1-year low of $95.44 and a 1-year high of $179.57. The firm has a market cap of $52.58 billion, a price-to-earnings ratio of 54.15, a price-to-earnings-growth ratio of 3.17 and a beta of 1.00. The company has a fifty day simple moving average of $162.20 and a two-hundred day simple moving average of $143.51.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, August 16th. The medical research company reported $1.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.11. Agilent Technologies had a return on equity of 26.12% and a net margin of 16.12%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the company posted $0.78 EPS. Agilent Technologies’s revenue for the quarter was up 25.8% on a year-over-year basis. Analysts expect that Agilent Technologies will post 4.31 EPS for the current year.

In related news, SVP Dominique Grau sold 9,033 shares of the stock in a transaction on Wednesday, August 18th. The stock was sold at an average price of $165.06, for a total value of $1,490,986.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A hedge fund recently raised its stake in Agilent Technologies stock. Morgan Stanley boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 2.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,154,775 shares of the medical research company’s stock after acquiring an additional 33,059 shares during the quarter. Morgan Stanley owned 0.38% of Agilent Technologies worth $170,688,000 at the end of the most recent quarter.

About Agilent Technologies

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.

See Also: Golden Cross

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with's FREE daily email newsletter.